Low-Molecular-Weight Protein Tyrosine Phosphatase Predicts Prostate Cancer Outcome by Increasing the Metastatic Potential

We identified the low-molecular-weight protein tyrosine phosphatase (LMWPTP) as a new treatment target and predictive marker for clinical follow-up in prostate cancer (PCa). LMWPTP is overexpressed in PCa and results in a more malignant phenotype. Moreover, it is an independent prognostic predictor of poor clinical outcome.